-

07:34:25 PM

LIVE Real Time BNTX Stock Market News

BNTX - BioNTech SE

04/19/21 4:00 AM

Nasdaq : BNTX

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY(R)

European Union exercises option under previous agreement to order 100 million additional doses of COMIRNATY (R), bringing total doses to 600 million for 27 EU member states All doses expected to be delivered in 2021 NEW YORK and MAINZ, GERMANY, April 19, 2021 -- Pfizer Inc. (NYSE:

RHEA-AI

neutral

04/01/21 6:45 AM

NYSE, Nasdaq : PFE, BNTX

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pivotal Phase 3 study through March 13, 2021, showing the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, was 91.3% effective

RHEA-AI

neutral

04/01/21 6:45 AM

Nasdaq : BNTX

Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study

Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose Vaccine was 100% effective in preventing severe disease as defined by the U.S.

RHEA-AI

neutral

03/31/21 6:45 AM

NYSE, Nasdaq : PFE, BNTX

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2 demonstrated 100% efficacy and robust antibody responses,

RHEA-AI

neutral

03/31/21 6:45 AM

Nasdaq : BNTX

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

In participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16-25 year old participants in an earlier analysis, and was well tolerated The companies plan to submit these data to the U.S. Food and Drug

RHEA-AI

neutral

03/30/21 6:30 AM

Nasdaq : BNTX

BioNTech Announces Full Year 2020 Financial Results and Corporate Update

BNT162b2 vaccine approved or authorized for emergency or temporary use in over 65 countries and regions after successful global Phase 3 trial demonstrated safety and efficacy in preventing COVID-19. More than 200 million doses of BNT162b2 supplied as of March 23, 2021, with signed orders for 1.4

RHEA-AI

neutral

03/26/21 9:45 AM

Nasdaq : BNTX

BioNTech provides Update on Vaccine Production Status at Marburg Manufacturing Site

MAINZ, GERMANY, March 26, 2021 -- BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part of the process, EMA has approved the production of the drug substance, the mRNA,

RHEA-AI

neutral

03/26/21 9:20 AM

Nasdaq : BNTX

EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union

New stability data show vaccine can be stored at -25?C to -15?C for a total of two weeks and support decentralized distribution plans for vaccination at general practitioners' offices Label update offers greater flexibility for distributing, storing and administering the vaccine within the European

RHEA-AI

positive

03/23/21 7:00 AM

Nasdaq : BNTX

BioNTech to Report Full Year Financial Results for 2020 and Provide Corporate Update on the Fourth Quarter on March 30, 2021

Mainz, Germany, March 23, 2021 - BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will announce its financial results for the fourth quarter 2020 on Tuesday, March 30 th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with

RHEA-AI

neutral

03/11/21 6:45 AM

NYSE, Nasdaq : PFE, BNTX

Real-World Evidence Confirms High Effectiveness of Pfizer-BioNTech COVID-19 Vaccine and Profound Public Health Impact of Vaccination One Year After Pandemic Declared

The Israel Ministry of Health (MoH), Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next